PO.MCB08.02 · 分子与细胞生物学

Copy number analysis of regulatory regions reveal recurrent promoter/enhancer somatic copy number alterations across >8,000 TCGA samples

海报缩略图:Copy number analysis of regulatory regions reveal recurrent promoter/enhancer somatic copy number alterations across >8,000 TCGA samples
编号 1978 展板 4 时间 4/20 09:00–12:00 区域 Section 23 主讲 Haruna Tomono, BS
分会场 Genomic Drivers of Cancer Pathogenesis
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Haruna Tomono1, Chunyang Bao2, Antonia Kowalewski1, David Lehotzky1, Ron Solan1, Matthew Leventhal1, Luis Antonio Corchete Sanchez1, David I. Heiman1, Samantha Van Seters1, Saveliy Belkin1, Sam Wiseman1, Brian P. Danysh1, Chip Stewart1, Vasuki Narasimha Swamy1, Gengchao Wang1, Xavi Loinaz1, Zachary Everton1, Gang-Hee Lee2, Won-Chul Lee2, Hansol Park2, Ryul Kim2, Young Seok Ju2, Esther Rheinbay1, Gad Getz1, Andrew D. Cherniack1, Matthew L. Meyerson3, Rameen Beroukhim3

1Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA,2Inocras Inc., San Diego, CA,3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

摘要 Abstract

Somatic copy number alterations (SCNAs) are frequent oncogenic events. Previous studies have identified recurrent gene-level SCNAs using DNA microarray and whole exome sequencing data. These studies have also identified focal amplifications of regulatory regions. High-throughput whole genome sequencing enables deeper, comprehensive analysis of these focal SCNAs in non-coding regions, potentially revealing novel drivers of oncogenesis. To this end, we systematically analyzed SCNAs and structural variants in WGS data from >8,000 tumor-normal pairs across 31 cancer types from The Cancer Genome Atlas (TCGA) using GISTIC2.0 to identify focal, recurrent promoter and enhancer SCNAs near known oncogenes and tumor suppressor genes. We leveraged structural variant calls to orthogonally validate our primary focal SCNA findings. We identified a recurrent amplification event specific to the EGFR promoter/enhancer region in a subset of IDH-wildtype glioblastoma samples. This suggests an additional SCNA-driven mechanism for EGFR upregulation, distinct from canonical gene body amplification or point mutations, in a fraction of these aggressive tumors. Our ongoing work aims to broaden the landscape of regulatory SCNAs across cancers and validate their transcriptional impact to provide new biological insights and candidate therapeutic targets.
利益披露 Disclosure
H. Tomono, None. C. Bao, Inocras Employment. A. Kowalewski, None.. D. Lehotzky, None.. R. Solan, None.. M. Leventhal, None.. L. Corchete Sanchez, None.. D. I. Heiman, None.. S. Van Seters, None.. S. Belkin, None.. S. Wiseman, None.. B. P. Danysh, None.. C. Stewart, None.. V. Narasimha Swamy, None.. G. Wang, None.. X. Loinaz, None.. Z. Everton, None. G. Lee, Inocras Employment. W. Lee, Inocras Employment. H. Park, Inocras Employment. R. Kim, Inocras Employment. Y. Ju, Inocras Employment. E. Rheinbay, Inocras ). G. Getz, IBM ). Pharmacyclics/Abbvie ). Bayer ). Genentech ). Calico ). Ultima Genomics ). Inocras ). Google ). Kite ). Novartis ). Scorpion Therapeutics Other Securities, Other, Founder, Consultant. Predicta Biosciences Other Securities, Other, Founder. Antares Therapeutics Other Securities. A. D. Cherniack, Bayer ). M. L. Meyerson, Bayer ), Patent, Other. Janssen ). Delve Bio Other. Isabl Other. Karyoverse Other. R. Beroukhim, KaryoVerse Therapeutics Stock. LOH Therapeutics Stock.

在会议检索中打开